Rigel Pharmaceuticals Total Assets 2010-2025 | RIGL

Rigel Pharmaceuticals total assets from 2010 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
Rigel Pharmaceuticals Annual Total Assets
(Millions of US $)
2024 $164
2023 $117
2022 $134
2021 $167
2020 $110
2019 $148
2018 $139
2017 $119
2016 $78
2015 $132
2014 $154
2013 $226
2012 $310
2011 $257
2010 $187
2009 $141
Rigel Pharmaceuticals Quarterly Total Assets
(Millions of US $)
2025-03-31 $176
2024-12-31 $164
2024-09-30 $139
2024-06-30 $128
2024-03-31 $127
2023-12-31 $117
2023-09-30 $115
2023-06-30 $117
2023-03-31 $124
2022-12-31 $134
2022-09-30 $116
2022-06-30 $128
2022-03-31 $149
2021-12-31 $167
2021-09-30 $187
2021-06-30 $202
2021-03-31 $216
2020-12-31 $110
2020-09-30 $123
2020-06-30 $138
2020-03-31 $143
2019-12-31 $148
2019-09-30 $156
2019-06-30 $156
2019-03-31 $173
2018-12-31 $139
2018-09-30 $123
2018-06-30 $141
2018-03-31 $99
2017-12-31 $119
2017-09-30 $71
2017-06-30 $85
2017-03-31 $101
2016-12-31 $78
2016-09-30 $89
2016-06-30 $99
2016-03-31 $108
2015-12-31 $132
2015-09-30 $139
2015-06-30 $148
2015-03-31 $166
2014-12-31 $154
2014-09-30 $163
2014-06-30 $182
2014-03-31 $203
2013-12-31 $226
2013-09-30 $240
2013-06-30 $262
2013-03-31 $283
2012-12-31 $310
2012-09-30 $194
2012-06-30 $214
2012-03-31 $234
2011-12-31 $257
2011-09-30 $276
2011-06-30 $290
2011-03-31 $166
2010-12-31 $187
2010-09-30 $201
2010-06-30 $196
2010-03-31 $217
2009-12-31 $141
2009-09-30 $164
2009-06-30 $88
2009-03-31 $114
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.338B $0.179B
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $80.630B 30.25
Zoetis (ZTS) United States $69.973B 26.11
Takeda Pharmaceutical (TAK) Japan $46.997B 9.35
Daiichi Sankyo, - (DSNKY) Japan $42.922B 22.00
BeOne Medicines - (ONC) Cayman Islands $27.080B 0.00
Sandoz Group AG (SDZNY) Switzerland $23.434B 0.00
Merck (MKKGY) Germany $16.421B 12.03
Summit Therapeutics (SMMT) United States $15.269B 0.00
Shionogi (SGIOY) Japan $14.428B 0.00
United Therapeutics (UTHR) United States $13.115B 11.60
Neurocrine Biosciences (NBIX) United States $12.524B 42.90
Orion OYJ (ORINY) Finland $10.594B 28.65
IPSEN (IPSEY) France $9.831B 0.00
Corcept Therapeutics (CORT) United States $7.569B 61.53
Stevanato Group S.p.A (STVN) Italy $7.053B 43.13
Madrigal Pharmaceuticals (MDGL) United States $6.344B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Grifols, S.A (GRFS) Spain $6.030B 0.00
Ionis Pharmaceuticals (IONS) United States $5.954B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.031B 15.30
Soleno Therapeutics (SLNO) United States $4.031B 0.00
Hypermarcas (HYPMY) Brazil $3.075B 20.23
Crinetics Pharmaceuticals (CRNX) United States $2.824B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.742B 9.61
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.451B 13.25
BioCryst Pharmaceuticals (BCRX) United States $2.113B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.016B 0.00
Indivior (INDV) United States $1.932B 8.19
Centessa Pharmaceuticals (CNTA) United Kingdom $1.660B 0.00
Endo (NDOI) United States $1.595B 0.00
ARS Pharmaceuticals (SPRY) United States $1.552B 0.00
Evotec AG (EVO) Germany $1.335B 0.00
Ocular Therapeutix (OCUL) United States $1.295B 0.00
Guardian Pharmacy Services (GRDN) United States $1.272B 0.00
Dyne Therapeutics (DYN) United States $1.173B 0.00
Harrow (HROW) United States $1.125B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.050B 21.00
Enliven Therapeutics (ELVN) United States $1.045B 0.00
Verve Therapeutics (VERV) United States $0.986B 0.00
Akebia Therapeutics (AKBA) United States $0.967B 0.00
Collegium Pharmaceutical (COLL) United States $0.958B 5.17
Avadel Pharmaceuticals (AVDL) Ireland $0.888B 0.00
Ardelyx (ARDX) United States $0.852B 0.00
Elite Pharmaceuticals (ELTP) United States $0.793B 0.00
Cronos Group (CRON) Canada $0.717B 0.00
Xeris Biopharma Holdings (XERS) United States $0.705B 0.00
Xencor (XNCR) United States $0.608B 0.00
KalVista Pharmaceuticals (KALV) United States $0.604B 0.00
Altimmune (ALT) United States $0.570B 0.00
USANA Health Sciences (USNA) United States $0.569B 12.37
Relay Therapeutics (RLAY) United States $0.547B 0.00
Regulus Therapeutics (RGLS) United States $0.546B 0.00
Bioventus (BVS) United States $0.538B 13.65
Theravance Biopharma (TBPH) United States $0.532B 0.00
AleAnna (ANNA) United States $0.504B 0.00
Zevra Therapeutics (ZVRA) United States $0.494B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.450B 0.00
Oruka Therapeutics (ORKA) United States $0.437B 0.00
Siga Technologies (SIGA) United States $0.437B 9.13
Tourmaline Bio (TRML) United States $0.427B 0.00
Organogenesis (ORGO) United States $0.410B 0.00
Liminatus Pharma (LIMN) United States $0.375B 0.00
Savara (SVRA) United States $0.356B 0.00
Aquestive Therapeutics (AQST) United States $0.323B 0.00
Heron Therapeutics (HRTX) United States $0.305B 0.00
Nature's Sunshine Products (NATR) United States $0.271B 24.86
Tonix Pharmaceuticals Holding (TNXP) United States $0.238B 0.00
Esperion Therapeutics (ESPR) United States $0.212B 0.00
Nanobiotix S.A (NBTX) France $0.211B 0.00
MediWound (MDWD) Israel $0.206B 0.00
OmniAb (OABI) United States $0.194B 0.00
ProKidney (PROK) United States $0.193B 0.00
4D Molecular Therapeutics (FDMT) United States $0.191B 0.00
Profound Medical (PROF) Canada $0.191B 0.00
Aldeyra Therapeutics (ALDX) United States $0.183B 0.00
Larimar Therapeutics (LRMR) United States $0.166B 0.00
Aclaris Therapeutics (ACRS) United States $0.157B 0.00
Galectin Therapeutics (GALT) United States $0.153B 0.00
Journey Medical (DERM) United States $0.152B 0.00
Innate Pharma SA (IPHYF) France $0.145B 0.00
Avita Medical (RCEL) United States $0.137B 0.00
VAXART, INC (VXRT) United States $0.132B 0.00
Lexeo Therapeutics (LXEO) United States $0.130B 0.00
Lyell Immunopharma (LYEL) United States $0.129B 0.00
Inhibikase Therapeutics (IKT) United States $0.123B 0.00
Protara Therapeutics (TARA) United States $0.118B 0.00
Achieve Life Sciences (ACHV) Canada $0.116B 0.00
Korro Bio (KRRO) United States $0.116B 0.00
Champions Oncology (CSBR) United States $0.115B 18.84
Ironwood Pharmaceuticals (IRWD) United States $0.114B 0.00
Nektar Therapeutics (NKTR) United States $0.106B 0.00
Fractyl Health (GUTS) United States $0.105B 0.00
Cardiol Therapeutics (CRDL) Canada $0.102B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.101B 0.00
Cassava Sciences (SAVA) United States $0.096B 0.00
Wellgistics Health (WGRX) United States $0.087B 0.00
Nutriband (NTRB) United States $0.087B 0.00
Surrozen (SRZN) United States $0.086B 0.00
Dominari Holdings (DOMH) United States $0.083B 0.00
Arch Biopartners (ACHFF) Canada $0.083B 0.00
Unicycive Therapeutics (UNCY) United States $0.080B 0.00
ESSA Pharma (EPIX) Canada $0.077B 0.00
Vivani Medical (VANI) United States $0.075B 0.00
Pyxis Oncology (PYXS) United States $0.072B 0.00
Inotiv (NOTV) United States $0.070B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.065B 48.33
Assertio Holdings (ASRT) United States $0.060B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
PMV Pharmaceuticals (PMVP) United States $0.057B 0.00
NRx Pharmaceuticals (NRXP) United States $0.056B 0.00
Rafael Holdings (RFL) United States $0.055B 0.00
Metagenomi (MGX) United States $0.054B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.054B 0.00
Gain Therapeutics (GANX) United States $0.053B 0.00
Telomir Pharmaceuticals (TELO) United States $0.052B 0.00
Context Therapeutics (CNTX) United States $0.051B 0.00
Avalo Therapeutics (AVTX) United States $0.050B 0.00
Century Therapeutics (IPSC) United States $0.050B 0.00
Klotho Neurosciences (KLTO) United States $0.050B 0.00
Prelude Therapeutics (PRLD) United States $0.049B 0.00
Mural Oncology (MURA) Ireland $0.042B 0.00
Iterum Therapeutics (ITRM) Ireland $0.040B 0.00
ElectroCore (ECOR) United States $0.038B 0.00
Karyopharm Therapeutics (KPTI) United States $0.038B 0.00
Acrivon Therapeutics (ACRV) United States $0.037B 0.00
Jupiter Neurosciences (JUNS) United States $0.037B 0.00
PolyPid (PYPD) Israel $0.033B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.033B 0.00
China SXT Pharmaceuticals (SXTC) China $0.029B 0.00
SCYNEXIS (SCYX) United States $0.029B 0.00
Enlivex Therapeutics (ENLV) Israel $0.026B 0.00
Tempest Therapeutics (TPST) United States $0.025B 0.00
FibroGen (FGEN) United States $0.023B 0.00
Relmada Therapeutics (RLMD) United States $0.023B 0.00
DURECT (DRRX) United States $0.021B 0.00
Natural Alternatives (NAII) United States $0.020B 0.00
BioVie (BIVI) United States $0.019B 0.00
Mannatech (MTEX) United States $0.019B 0.00
Carisma Therapeutics (CARM) United States $0.018B 0.00
BioLineRx (BLRX) Israel $0.018B 0.00
Ernexa Therapeutics (ERNA) United States $0.018B 0.00
Lipocine (LPCN) United States $0.018B 0.00
Vivos Therapeutics (VVOS) United States $0.016B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.016B 0.00
CASI Pharmaceuticals (CASI) China $0.016B 0.00
ProPhase Labs (PRPH) United States $0.014B 0.00
Lyra Therapeutics (LYRA) United States $0.014B 0.00
VYNE Therapeutics (VYNE) United States $0.014B 0.00
TherapeuticsMD (TXMD) United States $0.013B 0.00
Cosmos Health (COSM) United States $0.012B 0.00
Minerva Neurosciences (NERV) United States $0.012B 2.16
Scienture Holdings (SCNX) United States $0.012B 0.00
Citius Pharmaceuticals (CTXR) United States $0.011B 0.00
Phio Pharmaceuticals (PHIO) United States $0.011B 0.00
Mangoceuticals (MGRX) United States $0.011B 0.00
Ainos (AIMD) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
GlycoMimetics (CBIO) United States $0.010B 0.00
Talphera (TLPH) United States $0.009B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.009B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Alaunos Therapeutics (TCRT) United States $0.007B 0.00
SHINECO (SISI) China $0.007B 0.00
Incannex Healthcare (IXHL) Australia $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
Indaptus Therapeutics (INDP) United States $0.004B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
Heatwurx (PCSA) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Plus Therapeutics (PSTV) United States $0.003B 0.00
PainReform (PRFX) Israel $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Conduit Pharmaceuticals (CDT) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00